Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201812-01 Development of CDK7 inhibitor regulating Myc expression for cancer treatment(Oncology, Chemical) [2019-07-29]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Development of a nonclinical candidate CDK7 inhibitor for the treatment of Myc overexpressed cancer

Unmet Medical Need & Target Patients

Target patient

Myc positive patients

MCL1 positive patients

Liver cancer

TNBC

AML

6th most common cancer

39,230 new cases

27,176 deaths in US

Myc (+): 30~80%

15~20% of Breast cancer

~25,000 new cases in US

Myc (+): 54%

MCL1 (+): 35%

19,520 new cases

27,176 deaths in US

MCL1 (+): most patients

 

Unmet needs

5-year survival: < 12%

Nexavar®: low response rate and drug resistance

Needs: Biomarker driven drug

More aggressive

Needs: non-targeted therapy

 

 

5-year survival: <25%

Needs: a few targeted therapy

 

 

Status

Currently, candidate selection is ongoing.

Intellectual Property

Patent application in Sep. 2018

Competitive Advantages

CDK7 promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. It is known that MYC may drive tumor growth not only through their intrinsic influence on cellular proliferation but also through their regulation of immune checkpoints that enables evasion from immune surveillance. YPN005 showed significant anti-tumor activities for Myc-driven cancer models with down regulation of immune checkpoints such as PD-L1 and CD47. Therefore, YPN005 can be used for various cancer with Myc as a biomarker.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code